Barclays Starts Moderna (MRNA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mail
Get Alerts MRNA Hot Sheet
Price: $255.40 -1.15%
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Barclays analyst Gena Wang initiates coverage on Moderna (NASDAQ: MRNA) with a Overweight rating and a price target of $68.00.
For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.
Shares of Moderna closed at $56.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moderna (MRNA) call put ratio 1 call to 1 put into quarter results
- Citi Assumes Genting Bhd (GENT:MK) (GEBHY) at Buy
- Jones Trading Assumes Prime Medicine (PRME) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Barclays, Gena WangSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
